Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Pneumococcal conjugate vaccine Stories

2011-11-30 14:33:57

First of its kind study examines alternative immunization schedule occurrence rates in Washington state and pediatricians´ comfort level using alternative schedules Seventy-seven percent of Washington state pediatricians report that they are sometimes or frequently asked to provide alternative childhood vaccine schedules for their patients, according to a new study from Seattle Children´s Research Institute.  Researchers also found that 61 percent of Washington state...

2011-11-10 12:56:38

Advances lauded as Malawi becomes next developing country to introduce pneumococcal vaccine on Saturday -- World Pneumonia Day Vaccines against the primary cause of deaths from pneumonia in developing countries could save millions of lives and are highly cost-effective, according to a comprehensive new analysis to be released on Thursday, Nov. 10. In a paper published in the journal International Health, the authors estimate that two pneumococcal vaccines being introduced in the world's...

2011-10-19 05:31:58

(Ivanhoe Newswire) — Vaccinating young children against pneumonia in turn will protect the entire community.   In a randomized, controlled trial involving 21 villages in rural Gambia, the authors showed that vaccination of young children reduced carriage of vaccine serotype pneumococci (the type of pneumoccus contained in the vaccine) not only in the vaccinated children but also in vaccinated and non-vaccinated older children and adults. Furthermore, the study showed that...

2011-09-28 08:00:00

NEW YORK, Sept. 28, 2011 /PRNewswire/ -- The Prix Galien USA committee recognized excellence in scientific innovation that improves the state of human health last night during the fifth annual Prix Galien Awards Gala. The Pro Bono Humanum Award and the Prix Galien USA 2011 Awards for best biotechnology product and best pharmaceutical agent were presented at a ceremony held at the Museum of Natural History in New York City. The Prix Galien USA 2011 Award selection committee is an...

2011-09-22 21:21:26

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria. The findings, which could improve vaccines against pneumonia, appear in the September/October issue of mBio, the online journal of the American Society for Microbiology. Until recently, scientists thought that antibodies work against pneumococcal bacteria by killing them with the help of immune cells. However, several years ago, Einstein...

2011-06-15 04:00:00

SCHLIEREN, Switzerland, June 15, 2011 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France. "A number of serious bacterial diseases still lack vaccines while antibiotic resistance is growing and the costs for vaccines development is increasing," said Philippe Dro, CEO of GlycoVaxyn. "Setbacks in...

2011-05-17 11:00:00

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners. Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts. As part of the product...

2011-04-22 16:58:00

SWIFTWATER, Pa., April 22, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and children 9 months through...

2011-04-06 11:22:18

Using a cross-sectional study, Stefan Flasche and colleagues investigated the effects of the UK pneumococcal vaccination program on serotype-specific carriage and invasive pneumococcal disease. There are more than 90 Streptococcus pneumoniae serotypes that can cause invasive pneumococcal disease (IPD). The pneumococcal conjugate vaccine PCV7 contains antigens from seven serotypes responsible for IPD. Immunization with PCV7 prevents both IPD disease and carriage of these seven serotypes, but...

2011-03-31 06:30:00

BEIJING, March 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010. Business Highlights In March 2011, Sinovac reported positive preliminary Phase I clinical trial results in adults for its proprietary EV71 inactivated vaccine against hand, foot and mouth disease. Sinovac received approval from China's SFDA (State...